Skip to Content
Car Accidents
Truck Accidents
Medical MalpracticeProgressive Multifocal Leukoencephalopathy (PML) is a devastating diagnosis. It is similar to ALS and other progressive neurological diseases that slowly rob patients of their mobility and functioning. PML is caused by a virus that attacks the central nervous system. Once PML has developed, patients quickly experience a decline in their […]
Category: Defective Drugs
A startling article entitled, “Conflict of Interest in the Assessment of Thromboprophylaxis” appeared in the January 2012 issue of The Journal of Bone & Joint Surgery. A group of investigators were curious about the possibility of bias during evidence-based reviews and they conducted a retrospective study, centering on prescription choice […]
Pradaxa (also known as Dabigatran Etexilate) is an inactive “parent” drug that relies on the body’s metabolism to eventually manufacture a form of the drug that the body can use as an anti-coagulant, a process that occurs after the drug has been ingested by a patient. Anti-coagulants such as Warfarin […]
In late 2010, the FDA approved the drug called Pradaxa (dabigatran); manufactured by Boehringer Ingelheim. Pradaxa is a blood thinner and is supposed to be prescribed to patients who suffer from the cardiac disorder atrial fibrillation. Atrial Fibrillation is the most common form of abnormal heart rhythm. Patients who suffer […]
Has it simply become all about bean counters and number crunching for some drug companies?
If you can generate over $1.5.8 billion in sales for (5) years, for a drug you know is defective, can you afford to pay the claims that result from people being hurt or killed?
In 2010, the U.S. Food & Drug Administration approved Pradaxa (Dabigatran Etexilate). Pradaxa acts as a blood “thinner” and is promoted to reduce the risk of stroke and blood clots in people with atrial fibrillation. Atrial fibrillation, affecting over two million Americans, occurs when the heart does not beat properly […]
Pradaxa (dabigatran etexilate mesylate), a new oral anticoagulant, achieved Food & Drug Administration (“FDA”) approval on October 19, 2010. One notable advantage of using Pradaxa to replace Warfarin to prevent clot formation is the elimination of INR testing in patients taking Pradaxa. INR is the acronym for International Normalized Ratio, which is used to monitor the effectiveness of anticoagulant such as warfarin.
